Corneal Cross-Linking (CXL)

Corneal Cross-Linking Expert,
Dr. Ronald Gaster

Ribboflavin Instillation During CXLAs a leading ophthalmologist in Beverly Hills, California and Huntington Beach, California, Dr. Ronald N. Gaster is on the cutting edge of developments in eye surgery and disease.

Dr. Gaster is currently a principal investigator in a clinical trial under an FDA protocol approved by the Western Institutional Review Board (WIRB) studying the overall efficacy of corneal cross-linking (CXL) to corneal cross-linking (CXL) plus Intacs for keratoconus or post-LASIK ectasia or pellucid marginal degeneration.

Left: A cornea saturated with riboflavin. Right: A UV light shining into the cornea.
Corneal cross-linking uses riboflavin eye drops combined with ultraviolet light to stiffen and strengthen the corneal fibers and thus halt the progression of the disease process.

Dr. Gaster is interviewed by EyeWorld at the recent American Society of Cataract and Refractive Surgery meeting on Cross-Linking for Adolescents with Progressive Keratoconus

Dr. Gaster has been an invited speaker nationally and internationally on corneal cross-linking, presenting his results at numerous ophthalmology meetings. He was recently invited to speak at the Jules Stein Eye Institute at UCLA to present his results on corneal cross-linking for Pediatric patients with progressive keratoconus. He also discussed corneal cross-linking and the surgery was videotaped and shown on the Emmy-award winning TV show, “The Doctors.”

Corneal intacs on a finger.Corneal cross-linking (CXL) has recently been approved by the FDA for patients suffering from progressive keratoconus or corneal ectasia that strengthens corneal fibers and can halt the progression of keratoconus.

Intacs are implantable intra-corneal ring segments (see photo) that can also benefit patients suffering from keratoconus or ectasia by flattening a steep cornea.

Dr. Gaster uses a Femtosecond Laser to create the channels for insertion of the Intacs segments. Both of these modalities are significantly more effective than orthokeratology or gas permeable hard contact lenses used to try to reshape the cornea. More importantly, by cross-linking early in the disease process, patients may avoid the need for corneal transplantation in the future.

Patients suffering from any of these conditions are encouraged to schedule a consultation with Dr. Ronald N. Gaster to discuss their eligibility. Dr. Gaster is passionate about the new, effective advancements in the treatment of a variety of ocular diseases and looks forward to improving the ocular health of his patients with these discoveries.

Dr. Gaster at the 4th Biennial Asia Cornea Society Meeting